Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population.
Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population.
复制标题
基于中国人群，手术肿瘤组织，活检或细胞学样本对于非小细胞肺癌中表皮生长因子受体突变测试的适用性。
DOI：
10.1016/j.tranon.2014.10.008
复制
发表时间：
2014-12
影响因子：
5
通讯作者：
Shi, Yuankai
中科院分区：
文献类型：
--
作者：
Han, Xiaohong;Zhang, Zhishang;Wu, Di;Shen, Yinchen;Wang, Shuai;Wang, Lin;Liu, Yutao;Yang, Sheng;Hu, Xingsheng;Feng, Yun;Sun, Yan;Shi, Yuankai
背景技术背景：表皮生长因子受体（EGFR）突变状态在非小细胞肺癌（NSCLC）患者的治疗选择中至关重要;然而，检测材料的可用性在临床实践中仍然具有挑战性。在这项研究中，我们收集了手术切除组织，淋巴结活检和细胞学样本进行EGFR突变检测，并调查基因突变和临床特征之间的关联。方法：收集276例NSCLC腺癌标本，采用高灵敏度扩增难治突变系统方法进行EGFR突变检测，最终分析涉及临床病理特征。研究结果：在276份样本中，96%（265/276）的肿瘤获得了可评价的EGFR突变状态，所有样本中突变频率为55.8%（148/265），三种不同类型样本的检测成功率相当：手术切除肿瘤组织为97.4%（38/39），淋巴结活检标本为100%（108/108），细胞学标本为92.2%（119/129）。EGFR突变与性别、吸烟史、淋巴结转移状态（N分期）、原发肿瘤大小、检测组织来源和样本类型显著相关（P <0.05）。多因素分析再次证实吸烟史和原发肿瘤大小与EGFR突变相关。结论：与肿瘤组织相比，淋巴结活检和细胞学样本均适合用于NSCLC EGFR突变检测，考虑到EGFR突变率较高，应广泛检测基因状态，非吸烟史和较小的原发肿瘤大小是EGFR突变状态的独立指标。
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation status is crucial in treatment selection for non–small cell lung cancer (NSCLC) patients; however, the detection materials’ availability remains challenging in clinical practice. In this study, we collected surgical resection tissues, lymph node biopsy, and cytological samples for EGFR mutation testing and investigated the associations between gene mutation and clinical characteristics. METHODS: Two hundred and seventy-six NSCLC adenocarcinoma specimens were collected, and highly sensitive amplification refractory mutation system method was implemented for EGFR mutation detection, with clinicopathologic characteristics involved in the final analysis. RESULTS: In the total of 276 samples, 96% (265/276) of tumors obtained evaluable EGFR mutation status, the frequency of mutation was 55.8% (148/265) in all specimens, and three different type samples shared a comparable successful testing rate: 97.4% (38/39) in surgical tumor tissues, 100% (108/108) in lymph node biopsy samples, and 92.2% (119/129) in cytological samples. EGFR mutation was significantly associated with sex, smoking history, lymph node metastasis status (N stage), primary tumor size, testing tissues origin, and sample type (P < .05). Multivariate analysis reconfirmed that smoking history and primary tumor size shared significant correlation with EGFR mutation after adjustment. CONCLUSIONS: Both lymph node biopsy and cytological samples were suitable surrogates for EGFR mutation detection in NSCLC compared with tumor tissues, gene status should be detected widely considering the high EGFR mutation rate, and nonsmoking history together with smaller primary tumor size was an independent indicator of EGFR mutation status.
登录
查看更多内容
影响因子：
3.5
作者：
Aisner, Dara L.;Marshall, Carrie B.
通讯作者：
Marshall, Carrie B.
影响因子：
158.5
作者：
Mok, Tony S.;Wu, Yi-Long;Fukuoka, Masahiro
通讯作者：
Fukuoka, Masahiro
影响因子：
158.5
作者：
Rosell, Rafael;Moran, Teresa;Taron, Miquel
通讯作者：
Taron, Miquel
亚洲晚期非小细胞腺癌组织学肺癌患者 EGFR 突变的前瞻性分子流行病学研究 (PIONEER)。
DOI：
10.1097/jto.0000000000000033
发表时间：
2014-02
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Shi Y;Au JS;Thongprasert S;Srinivasan S;Tsai CM;Khoa MT;Heeroma K;Itoh Y;Cornelio G;Yang PC
通讯作者：
Yang PC
DOI：
10.1164/rccm.201202-0294oc
发表时间：
2012-06-15
影响因子：
24.7
作者：
Navani N;Brown JM;Nankivell M;Woolhouse I;Harrison RN;Jeebun V;Munavvar M;Ng BJ;Rassl DM;Falzon M;Kocjan G;Rintoul RC;Nicholson AG;Janes SM
通讯作者：
Janes SM